Source comparison
Tesofensine MOTS-c Stack Appetite and Metabolism Stack Protocol 2026: Comparison Table
Primary Mechanism Norepinephrine/dopamine/serotonin reuptake inhibition in CNS AMPK activation via mitochondrial retrograde signalling Non-overlapping pathways. No receptor competition or enzyme saturation Dosing Frequency Once daily (oral) 2–3× weekly (subcut
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Norepinephrine/dopamine/serotonin reuptake inhibition in CNS
- AMPK activation via mitochondrial retrograde signalling
- Non-overlapping pathways. No receptor competition or enzyme saturation
- Dosing Frequency
- Once daily (oral)
- 2–3× weekly (subcutaneous)
- Tesofensine's 8-day half-life allows single daily dose; MOTS-c's short half-life requires multiple weekly administrations
- Half-Life
- ~8 days
- 4–6 hours
- Steady-state tesofensine reached at 4–5 weeks; MOTS-c effects peak 1–2 hours post-injection
- Appetite Effect
- Direct suppression via hypothalamic monoamine signalling
- Indirect. Improves insulin sensitivity, reducing postprandial glucose spikes that trigger hunger
- Tesofensine provides immediate intake reduction; MOTS-c stabilises hunger signalling metabolically
- Metabolic Effect
- 6–10% increase in resting energy expenditure (thermogenesis)
- 15–20% improvement in glucose uptake and insulin sensitivity in skeletal muscle
- Complementary. Tesofensine increases burn rate, MOTS-c prevents adaptive thermogenesis
- Cardiovascular Load
- Moderate (5–8 bpm HR increase, 3–5 mmHg systolic BP increase)
- Minimal (no direct adrenergic effects)
- Stack requires baseline cardiovascular assessment. Avoid in patients with uncontrolled hypertension